Anticancer Efficacy of Self-Nanoemulsifying Drug Delivery System of Sunitinib Malate
- 15 June 2017
- journal article
- research article
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 19 (1) , 123-133
Abstract
Sunitinib malate (SM) is reported as a weakly soluble drug in water due to its poor dissolution rate and oral bioavailability. Hence, in the current study, various “self-nanoemulsifying drug delivery systems (SNEDDS)” of SM were prepared, characterized and evaluated for the enhancement of its in vitro dissolution rate and anticancer efficacy. On the basis of solubilization potential of SM in various excipients, “Lauroglycol-90 (oil), Triton-X100 (surfactant) and Transcutol-P (cosurfactant)” were selected for the preparation of SM SNEDDS. SM-loaded SNEDDS were developed by spontaneous emulsification method, characterized and evaluated for “thermodynamic stability, self-nanoemulsification efficiency, droplet size, polydispersity index (PDI), zeta potential (ZP), surface morphology, refractive index (RI), the percent of transmittance (% T) and drug release profile.” In vitro dissolution rate of SM was significantly enhanced from an optimized SNEDDS in comparison with SM suspension. The optimized SNEDDS of SM with droplet size of 42.3 nm, PDI value of 0.174, ZP value of −36.4 mV, RI value of 1.339, % T value of 97.3%, and drug release profile of 95.4% (after 24 h via dialysis membrane) was selected for in vitro anticancer efficacy in human colon cancer cells (HT-29) by MTT assay. MTT assay indicated significant anticancer efficacy of optimized SM SNEDDS against HT-29 cells in comparison with free SM. The results of this study showed the great potential of SNEDDS in the enhancement of in vitro dissolution rate and anticancer efficacy of poorly soluble drug such as SM.Keywords
This publication has 49 references indexed in Scilit:
- Synergistic inhibition of sunitinib and ethaselen against human colorectal cancer cells proliferationBiomedicine & Pharmacotherapy, 2016
- Drug compound characterization by mass spectrometry imaging in cancer tissueArchives of Pharmacal Research, 2015
- The Multi-Targeted Kinase Inhibitor Sunitinib Induces Apoptosis in Colon Cancer Cells via PUMAPLOS ONE, 2012
- New Strategies for Advanced Neuroendocrine Tumors in the Era of Targeted TherapyClinical Cancer Research, 2012
- Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children’s Oncology Group studyCancer Chemotherapy and Pharmacology, 2011
- Clinical Pharmacokinetics of Tyrosine Kinase InhibitorsClinical Pharmacokinetics, 2011
- A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology PatientsClinical Cancer Research, 2009
- Stability of Sunitinib in Oral SuspensionAnnals of Pharmacotherapy, 2008
- A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off periodCancer Chemotherapy and Pharmacology, 2007
- Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With CancerJournal of Clinical Oncology, 2006